Hims & Hers Makes a Bet on Labs

Key Concepts

• Hims & Hers Growth
• Biomarker Testing
• Primary Care Expansion
• New Revenue Streams
• Market Disruption
• Subscriber Growth Potential
• Valuation Growth

Hims & Hers: A Phenomenal Growth Story and Future Potential

Hims & Hers has demonstrated exceptional growth, achieving a remarkable 77% growth rate since 2019, positioning it as a significant "compounder" in the market. This impressive trajectory is expected to continue, particularly with the introduction of a new, innovative product offering.

Biomarker Testing: A New Frontier for Hims & Hers

The company has launched a new biomarker testing service, offering customers access to detailed health insights. The pricing structure is as follows:

• $199 per year: Provides access to 50 biomarkers.
• $499 per year: Offers two tests annually, covering 120 biomarkers.

While this testing service itself represents a positive revenue stream, its true strategic value lies in its potential to unlock a multitude of new product categories and services.

Expanding into Primary Care and New Verticals

The biomarker testing initiative is a strategic move to bring Hims & Hers closer to the primary care sector. The tests provide crucial indications across various health domains, including:

• Heart health
• Metabolism
• Hormones
• Kidney function
• Liver function

This expansion into comprehensive health diagnostics is anticipated to open up significant new revenue streams and allow the company to enter diverse new verticals.

Subscriber Growth and Market Valuation

The company's ability to attract and retain customers is a key driver of its future success. Hims & Hers has a realistic target of growing its subscriber base from just over two million to over 10 million by the end of the decade.

This substantial subscriber growth is expected to fuel a significant increase in market valuation. Currently valued at an $8 billion market cap, the company is projected to reach over $100 billion in valuation within the next 5 to 10 years. This growth trajectory positions Hims & Hers as a disruptive force within the $400 billion pharmaceutical business.

Conclusion and Key Takeaways

Hims & Hers is a compelling growth story with substantial future potential. The introduction of its biomarker testing service is a pivotal step, not only as a revenue generator but as a catalyst for expanding into primary care and new service verticals. The company's ambitious subscriber growth targets, coupled with its innovative approach, suggest a significant disruption of the pharmaceutical market and a remarkable increase in its market valuation. Investors and observers are advised to closely monitor Hims & Hers, particularly its advancements in lab testing, which are poised to unlock significant new opportunities.